Showing 1771-1780 of 9336 results for "".
- Timber's Topical Isotretinoin Shows Benefit Across CI Subtypeshttps://practicaldermatology.com/news/timbers-topical-isotretinoin-shows-benefit-across-ci-subtypes/2461131/TMB-001, a topical isotretinoin formulated using Timber Pharmaceuticals’ patented IPEG™ delivery system, shows benefit in the treatment of congenital ichthyosis (CI), regardless of the subtype. Findings are being presented in a late-breaking presentation of a sub-analysis of the Phase 2b CONTROL st…
- Tremfya Safe, Effective Across Broad Patient Subpopulations Through 5 Years: Analysishttps://practicaldermatology.com/news/tremfya-safe-effective-across-broad-patient-subpopulations-through-five-years-analysis/2461130/Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson can provide a consistent, high degree of durable skin clearance through 5 years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO), based on an analysis of da…
- Poster: Interim Data Show Safety, Efficacy of Adbry for More than Three Yearshttps://practicaldermatology.com/news/poster-interim-data-show-safety-efficacy-of-adbry-for-more-than-three-years/2461129/Interim data support the long-term safety and efficacy profile of Adbry™ (tralokinumab-ldrm) for up to 3.5 years in adult patients with moderate-to-severe atopic dermatitis (AD). Results were shared as a poster presentation at the American Academy of Dermatology (AAD) 2022 Annual Meeting. Adbry, a…
- Compulink Partners with Promptly for New Suite of Serviceshttps://practicaldermatology.com/news/compulink-partners-with-promptly-for-new-suite-of-services/2461127/Compulink Healthcare Solutions has partnered with Promptly to launch Advantage Patient Experience™, a suite of easy-to-use features intended to provide patients with the latest in mobile device convenience, while simultaneously reducing the administrative burden on office staff. The new tools are …
- Update: Skin Reactions to COVID-19 and Its Vaccineshttps://practicaldermatology.com/news/update-skin-reactions-to-covid-19-and-its-vaccines/2461125/Thanks to a comprehensive COVID-19 dermatology registry, dermatologists now have gathered a great deal of data on skin reactions caused by COVID-19 and its vaccines. “Early April of 2020, the American Academy of Dermatology and the International League of Dermatologic Societies put together a CO…
- Janssen Launches VISIBLE Study of PsO in People of Colorhttps://practicaldermatology.com/news/janssen-launched-visible-study-of-pso-in-people-of-color/2461121/The Janssen Pharmaceutical Companies of Johnson & Johnson has initiated VISIBLE, a first-of-its-kind, large-scale prospective clinical study dedicated to people of color living with moderate to severe plaque and/or scalp psoriasis (PsO). VISIBLE will further evaluate the efficacy and safety of Tre…
- Study: Laser Surgery Lawsuits Less Likely with Physician Operatorshttps://practicaldermatology.com/news/study-laser-surgery-lawsuits-less-likely-with-physician-operators/2461113/The majority of liability claims due to a cutaneous laser surgery device between 2012 and 2020 involved a non-physician operator, according to a new study in the March 2022 issue of Dermatologic Surgery. Researchers analyzed cases of liability claims due to a cutaneous laser surgery device that to…
- Dermatology Refresher Symposium for PAs and NPs Coming to San Antoniohttps://practicaldermatology.com/news/dermatology-refresher-symposium-for-pas-and-nps-coming-to-san-antonio/2461112/The 2nd Annual Dermatology Refresher Symposium (DRS) for NPs and PAs comes to Texas next month. The in-person program will be held on April 8-10, 2022 at the Grand Hyatt San Antonio River Walk in San Antonio. DRS is offering complimentary registration to NPs and PAs who graduated in 2020-2022. M…
- First Austrian Skin Cancer Patients Treated with Rhenium-SCT in New Studyhttps://practicaldermatology.com/news/first-austrian-skin-cancer-patients-treated-with-rhenium-sct-in-new-study/2461110/The first Austrian patients have been treated in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT– for the treatment of non-melanoma skin cancer), according to OncoBeta GmbH. "This is an important step for better understanding efficacy and patient outcomes…
- It's Grant Season: NEA Announces 2022 Eczema Research Grant Cyclehttps://practicaldermatology.com/news/its-grant-season-nea-announces-2022-eczema-research-grant-cycle-1/2461109/The National Eczema Association's (NEA) 2022 research grant cycle is now open, with awards totaling $760,000. Applications must be received by June 1, 2022, at 5 p.m. PDT, and recipients will be announced in October 2022. As the largest private nonprofit funder of eczema research, NEA has investe…